MOLN — Molecular Partners AG Income Statement
0.000.00%
Last trade - 00:00- CH₣127.96m
- -CH₣19.04m
- CH₣4.97m
Annual income statement for Molecular Partners AG, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 9.34 | 9.75 | 190 | 7.04 | 4.97 |
| Cost of Revenue | |||||
| Gross Profit | 8.78 | 9.69 | 189 | 7.03 | 4.96 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 67.7 | 73.2 | 73 | 68.1 | 66.2 |
| Operating Profit | -58.3 | -63.4 | 117 | -61.1 | -61.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -62.8 | -63.8 | 118 | -62 | -54 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -62.8 | -63.8 | 118 | -62 | -54 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -62.8 | -63.8 | 118 | -62 | -54 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -62.8 | -63.8 | 118 | -62 | -54 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.51 | -2.06 | 3.63 | -1.89 | -1.59 |
| Dividends per Share |